Researches on Surgical Pathology of Hepatobiliary Tumors in EHBH

Cong, Wen-Ming

doi:10.1007/978-981-10-3536-4_3

Cited by 3 publications

(11 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unlike previous studies, in which a peritumoral expansion distance of 1, 3, or 5 mm was set ( 21 , 22 ), we selected a radial distance of 10 mm in this study. According to the guideline of pathological sampling of HCC specimens, liver tissue within a 10 mm distance was defined as the adjacent peritumoral region ( 36 ). The chances of microvascular invasion are high in this region, and therefore, 10 mm may represent a better peritumoral region correlated with prognosis evaluation ( 37 ).…”

Section: Discussionmentioning

confidence: 99%

Radiomics Analysis on Multiphase Contrast-Enhanced CT: A Survival Prediction Tool in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization

Meng

Wang

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Patients with HCC receiving TACE have various clinical outcomes. Several prognostic models have been proposed to predict clinical outcomes for patients with hepatocellular carcinomas (HCC) undergoing transarterial chemoembolization (TACE), but establishing an accurate prognostic model remains necessary. We aimed to develop a radiomics signature from pretreatment CT to establish a combined radiomics-clinic (CRC) model to predict survival for these patients. We compared this CRC model to the existing prognostic models in predicting patient survival. This retrospective study included multicenter data from 162 treatment-naïve patients with unresectable HCC undergoing TACE as an initial treatment from January 2007 and March 2017. We randomly allocated patients to a training cohort ( n = 108) and a testing cohort ( n = 54). Radiomics features were extracted from intra- and peritumoral regions on both the arterial phase and portal venous phase CT images. A radiomics signature (Rad-signature) for survival was constructed using the least absolute shrinkage and selection operator method in the training cohort. We used univariate and multivariate Cox regressions to identify associations between the Rad- signature and clinical factors of survival. From these, a CRC model was developed, validated, and further compared with previously published prognostic models including four-and-seven criteria, six-and-twelve score, hepatoma arterial-embolization prognostic scores, and albumin-bilirubin grade. The CRC model incorporated two variables: The Rad-signature (composed of features extracted from intra- and peritumoral regions on the arterial phase and portal venous phase) and tumor number. The CRC model performed better than the other seven well-recognized prognostic models, with concordance indices of 0.73 [95% confidence interval (CI) 0.68–0.79] and 0.70 [95% CI 0.62–0.82] in the training and testing cohorts, respectively. Among the seven models tested, the six-and-12 score and four-and-seven criteria performed better than the other models, with C-indices of 0.64 [95% CI 0.58–0.70] and 0.65 [95% CI 0.55–0.75] in the testing cohort, respectively. The CT radiomics signature represents an independent biomarker of survival in patients with HCC undergoing TACE, and the CRC model displayed improved predictive performance.

show abstract

Section: Discussionmentioning

confidence: 99%

Radiomics Analysis on Multiphase Contrast-Enhanced CT: A Survival Prediction Tool in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization

Meng

Wang

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“… Macroscopic description of specimens [62]: all surgical samples submitted should be thoroughly inspected, and the following details should be specifically described: size, number, color, and texture of tumors; their relationship with blood vessels and bile ducts; encapsulation status; lesions in the non-neoplastic liver tissue; type of liver cirrhosis; distance between tumor and incisal margin; and status of the incisal margin. Microscopic observations and descriptions [62]: all specimens collected should be thoroughly observed, and the pathologic diagnosis may be based on the 2019 WHO diagnostic criteria for HCC [58]. The following information should be specifically described: The degree of differentiation of tumor cells may be described according to the internationally used Edmondson-Steiner grading system or the high, moderate, and low classification recommended by the WHO. The histological morphology of HCC is usually divided into microtrabecular, macrotrabecular, pseudoglandular, and compact types. Special subtypes of HCC include fibrolamellar, cirrhotic, clear cell, fatty change, macrotrabecular-massive, chromophobe cell, neutrophil-rich, lymphocyte-rich, and undifferentiated types. Degree and range of tumor necrosis, lymphocyte infiltration, and stromal fibrosis. The growth pattern of HCC including perineoplastic infiltration, capsule invasion or breakthrough, MVI, and the presence of satellite nodules. Evaluation of chronic liver diseases: HCC is often accompanied by varying degrees of chronic viral hepatitis or liver cirrhosis.…”

Section: Pathologic Diagnosis Of Hccmentioning

confidence: 99%

“…Although current anti-HBV and anti-HCV therapies may significantly reduce the risk of HCC, the development of HCC is not fully prevented [10]. The age-Male-AlBi-Platelets score (aMAP score), a risk assessment model developed by Chinese scholars that is indicated for a variety of chronic liver diseases and various types of HCC, can be used to categorize a population with liver diseases into risk groups for HCC: low (score 0-50), intermediate (score [50][51][52][53][54][55][56][57][58][59][60], and high (score 60-100) risk, with annual HCC incidence rates of 0-0.2%, 0.4-1%, and 1.6-4%, respectively [11] (evidence level 2, recommendation B). Screening for HCC may be performed using ultrasonography (US) and serum alpha-fetoprotein (AFP) and is recommended at least every 6 months in high-risk populations [9] (evidence level 2, recommendation A).…”

Section: Screening and Diagnosismentioning

confidence: 99%

“…Key Points of Histologic Examination of HCC 1. Macroscopic description of specimens [62]: all surgical samples submitted should be thoroughly inspected, and the following details should be specifically described: size, number, color, and texture of tumors; their relationship with blood vessels and bile ducts; encapsulation status; lesions in the non-neoplastic liver tissue; type of liver cirrhosis; distance between tumor and incisal margin; and status of the incisal margin. 2.…”

Section: Key Points For Specimen Retrievalmentioning

confidence: 99%

See 1 more Smart Citation

Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)

Zhou¹,

Sun²,

Wang³

et al. 2023

Liver Cancer

View full text Add to dashboard Cite

Background: Primary liver cancer, around 75%–85% are hepatocellular carcinoma in China, is the fourth most common malignancy and the second leading cause of tumor-related death, thereby posing a significant threat to the life and health of the Chinese people. Summary: Since the publication of Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China in June 2017, which were updated by the National Health Commission in December 2019, additional high-quality evidence has emerged from researchers worldwide regarding the diagnosis, staging, and treatment of liver cancer, that requires the guidelines to be updated again. The new edition (2022 Edition) was written by more than 100 experts in the field of liver cancer in China, which not only reflects the real-world situation in China, but also may re-shape the nationwide diagnosis and treatment of liver cancer. Key Messages: The new guideline aims to encourage the implementation of evidence-based practice, and improve the national average five-year survival rate for patients with liver cancer, as proposed in the "Health China 2030 Blueprint."

show abstract

“…Recommendation 9: In the pathological report of iCCA, it is important to illustrate the pathological characteristics associated with the risks of postoperative recurrence and metastasis to assist in the clinical treatment planning. 13 , 44 , 90 These should include the gross type, histological subtype, immunophenotype, differentiation grade, microvascular invasion, biological behavior, status of surgical margin, pathological tumor–node–metastasis stage, background of liver disease, and other important relevant information. To improve the homogeneity of pathological diagnosis of iCCA, the use of a template for pathological diagnostic reporting should be encouraged (moderate-quality evidence and strong recommendation).…”

Section: Summary Of Key Points Of the Pathological Diagnosis Of Iccamentioning

confidence: 99%

Expert Consensus on Pathological Diagnosis of Intrahepatic Cholangiocarcinoma (2022 version)

Han¹,

Zhang²,

Sheng³

et al. 2023

J Clin Transl Hepatol

View full text Add to dashboard Cite

Intrahepatic cholangiocarcinoma (iCCA) can originate from the large bile duct group (segment bile ducts and area bile ducts), small bile duct group (septal bile ducts and interlobular bile ducts), and terminal bile duct group (bile ductules and canals of Hering) of the intrahepatic biliary tree, which can be histopathological corresponding to large duct type iCCA, small duct type iCCA and iCCA with ductal plate malformation pattern, and cholangiolocarcinoma, respectively. The challenge in pathological diagnosis of above subtypes of iCCA falls in the distinction of cellular morphologies, tissue structures, growth patterns, invasive behaviors, immunophenotypes, molecular mutations, and surgical prognoses. For these reasons, this expert consensus provides nine recommendations as a reference for standardizing and refining the diagnosis of pathological subtypes of iCCA, mainly based on the 5 th edition of the World Health Organization Classification of Tumours of the Digestive System.

show abstract

Researches on Surgical Pathology of Hepatobiliary Tumors in EHBH

Cited by 3 publications

References 18 publications

Radiomics Analysis on Multiphase Contrast-Enhanced CT: A Survival Prediction Tool in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization

Radiomics Analysis on Multiphase Contrast-Enhanced CT: A Survival Prediction Tool in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization

Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)

Expert Consensus on Pathological Diagnosis of Intrahepatic Cholangiocarcinoma (2022 version)

Contact Info

Product

Resources

About